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Background: Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased
serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and
animal models support the hypothesis that omalizumab inhibits IgE synthesis by B cells and causes elimination of
IgE-expressing cells either by induction of apoptosis or induction of anergy or tolerance.
Methods: We examined the influence of omalizumab on human tonsillar B cell survival and on the genes involved
in IgE synthesis. Tonsillar B cells were stimulated with IL-4 plus anti-CD40 antibody to induce class switch
recombination to IgE production in the presence or absence of omalizumab. Cell viability was assessed and RNA
extracted to examine specific genes involved in IgE synthesis.
Conclusions: We found that omalizumab reduced viable cell numbers but this was not through induction of
apoptosis. IL-4R and germline Cε mRNA levels were decreased as well as the number of membrane IgE+ cells in B
cells treated with omalizumab. These data suggest that omalizumab may decrease IgE synthesis by human B cells
by specifically targeting membrane IgE-bearing B cells and inducing a state of anergy.
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IgE is responsible for type I hypersensitivity reactions such
as allergic asthma and allergic rhinitis. Direct correlations
have been noted between asthma and serum IgE levels [1].
One approach to controlling allergic diseases has been the
development of a monoclonal antibody that binds to IgE.
To be effective the anti-IgE must bind only free IgE or
membrane IgE present on the surface of B cells. However,
the antibody should not bind to IgE bound to either the
high affinity or low affinity IgE receptor. One such anti-
body is omalizumab. Omalizumab (Xolair®; Genentech/
Novartis) is a recombinant humanized monoclonal anti-
IgE IgG1 kappa antibody used in the treatment of allergic
asthma. Omalizumab binds free IgE in serum and
membrane-expressed IgE on B cells [2]. In clinical trials,
administration of omalizumab either intravenously or sub-
cutaneously significantly reduced serum levels of IgE and
asthmatic symptoms [3-5].* Correspondence: machan@cmh.edu
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reproduction in any medium, provided the orSeveral studies have examined the molecular and cellu-
lar targets of omalizumab using samples from allergic
asthmatic subjects treated with omalizumab. A significant
decrease in IgE secretion and B cell number was noted in
cultured peripheral blood mononuclear cells [6]. Also,
downregulation of the cytokines IL-2 and IL-13 has been
seen in T cells [7]. Djukanovic et al. [8] noted reductions
in the numbers of IgE+ stained cells and eosinophils in
airway mucosa from bronchial biopsies. Reduced cell
numbers of IgE+ stained cells and eosinophils were also
seen in nasal biopsy specimens from allergic rhinitis
patients treated with omalizumab [9]. The reduction in
the number of eosinophils appeared to be due to the in-
duction of apoptosis since the percentage of Annexin V+
cells was significantly increased in omalizumab recipients
[7]. Although the precise mechanism was not elucidated,
it was suggested that elimination of circulating IgE by
omalizumab might result in increased apoptosis of eosino-
phils. An apoptotic mechanism has also been proposed as
a mechanism of action by omalizumab to account for the
reduction in IgE synthesis by membrane IgE-bearing B
cells [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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omalizumab on human tonsillar B cell survival and on
the genes involved in IgE regulation. B cells produce IgE
after heavy chain class switching from IgM, IgG or IgA
and this is mediated by IL-4 or IL-13 [11,12]. Our results
show that omalizumab reduced the number of mem-
brane IgE-bearing B cells induced by stimulation using
IL-4 plus anti-CD40. However this was not due to the




Tonsillar tissue from 27 tonsils from children under the
age of 10 yrs was obtained from the Department of Path-
ology at Children’s Mercy Hospital, Kansas City, MO
within 4 - 6 h of tonsillectomy. The tissues utilized were
those that were in excess of clinical needs and would have
otherwise been discarded. All identifiers were removed by
pathology staff from the tissue before the tissue was
received and processed by our laboratory. The protocol
was approved by the Pediatric Institutional Review Board
of Children’s Mercy Hospitals and Clinics. Since the
tissues were deemed to be scavenged specimens the
Pediatric Institutional Review Board of Children’s Mercy
Hospitals and Clinics waived the need for written
informed consent from the participants and classified the
protocol to be non-human subjects research.
Cell isolation
B cells were isolated from tonsillar tissue as we have rou-
tinely done and described [13]. Briefly, tonsillar tissue was
teased apart and cells diluted in HBSS (Gibco/Invitrogen,
Carlsbad, CA). Mononuclear cells were then isolated by
Ficoll-Paque™ (GE Healthcare Bioscience AB, Piscataway,
NJ) density gradient centrifugation and subsequently B
cells were obtained using a B cell enrichment kit (EASY
SEP, Stemcell Technologies, Vancouver, BC, Canada). In
some instances B cells were further separated into naïve
and memory subsets using naïve and memory B cell isola-
tion kits (Stemcell Technologies). All cells were cultured in
RPMI1640 supplemented with 10% FBS (Hyclone, Logan
UT), 2 mM glutamine (Gibco/Invitrogen), 100 U/mL peni-
cillin (Gibco/Invitrogen), and 100 μg/mL streptomycin
(Gibco/Invitrogen). The percentage of CD19+ cells ranged
from 98.9 - 99.9% after B cell enrichment.
Cell stimulation
Tonsillar B cells at a concentration of 1 × 106/mL in
supplemented RPMI1640 were treated with 400 U/mL
recombinant IL-4 (eBioscience, San Diego, CA) plus 1
μg/mL anti-CD40 (eBioscience) in the presence or
absence of omalizumab (Novartis Pharmaceuticals Corp,
East Hanover, NJ) or control antibody (human IgGκ)(Southern Biotech, Birmingham, AL). Omalizumab was
reconstituted in sterile PBS at a concentration of 15 mg/mL.
Dilutions of omalizumab were made in RPMI1640. In
some instances the cells were pre-treated with FcR
blocking reagent (Miltenyi, Auburn, CA). At the indicated
times, viable cell numbers were enumerated by their
ability to exclude the dye trypan blue (Sigma–Aldrich,
St. Louis, MO). Culture supernatant fluid was harvested
for IL-6 quantification by ELISA (eBioscience).
Quantitative polymerase chain reaction (qRT-PCR)
Tonsillar B cells at a concentration of 1 × 106/mL were left
non-treated or were treated as described above. Cytoplas-
mic RNA was extracted from the cells using the RNeasy
Mini kit (Qiagen, Valencia, CA) and cDNA was subse-
quently synthesized using the High Capacity cDNA kit
(Applied Biosystems, Foster City, CA). Quantitative PCR
reactions were set up in optical 96-well reaction plates in a
final volume of 25 μL containing 12.5 μL of 2 × SYBR®
Green master mix (SABiosciences, Frederick, MD), sterile
water, 50 ng cDNA and 200 nM IL-4R alpha primers
(SABiosciences) or GAPDH primers, (SABiosciences) or
300 nM germline Cε primers (forward 5’ – CACA-
TCCACAGGCACCAAAT – 3’; reverse 5’ – ATCAC-
CGGCTCCGGGAAGTA – 3’, IDT, Coralville, IA), or
CD23a primers (forward 5’ – CCATGGAGGAAGGT-
CAATATT – 3’; reverse 5’ – CTCTCTTCCAGCTGTT-
TTAGA – 3’, IDT) or CD23b primers (forward 5’ –
CATAATGAATCCTCCAAGCCA – 3’; reverse 5’ –
CTTGGAAACTTGAGAGACGTT – 3’ IDT). PCR cyc-
ling conditions were 95°C for 10 min and then 40 cycles of
95°C for 15 sec, and 60°C for 1 min using a 7500 Real
Time PCR System (Applied Biosystems). For each sample
the gene of interest was normalized to GAPDH using the
ΔΔCt method to calculate relative fold difference in mRNA
levels compared to non-treated samples. Comparisons
between groups were made using the paired t-test, p < 0.05.
Flow cytometry
Purity of B cells, cell viability and apoptotic cells were
evaluated by flow cytometry (Accuri Cytometers Inc.,
Ann Arbor, MI) using anti-human CD19 conjugated to
PE, (clone HIB19), APC-conjugated anti-human CD27
(clone M-T271), FITC-conjugated anti-human IgD
(clone IAb-2), 7-AAD and PE-conjugated Annexin V
(BD Pharmingen, San Diego, CA), respectively. The cells
were stained using 15 μL of each antibody per million
cells. To evaluate proliferation the cells were stained
with 2.5 μM CFSE (Invitrogen) prior to stimulation with
IL-4 plus anti-CD40 in the presence or absence of
omalizumab. For surface IgE expression cells were
stained with either 15 μL/106 cells PE-conjugated anti-
human IgE (clone MHE-18, BioLegend, San Diego, CA)
or 10 μL/106 cells APC-conjugated anti-human IgE
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dicated. Flow cytometric analysis was performed using
Accuri C6-CFlow software (Accuri Cytometer Inc.). Un-
stained cells or non-treated cells (Annexin V/7-AAD,
CFSE experiments) were used to establish gates.
Results and discussion
Omalizumab reduced the number of membrane IgE+ B
cells
The combination of IL-4 plus anti-CD40 is known to
induce class switching to secretion of IgE by human B
cells [11,12]. To determine if omalizumab influenced the
ability of IL-4 plus anti-CD40 to induce B cells to
synthesize IgE, B cells were evaluated by flow cytometry
for the number of membrane IgE+ cells after treatment
for 4 days with IL-4 plus anti-CD40 in the presence or
absence of omalizumab. Figure 1A illustrates that
omalizumab significantly decreased the number of mem-
brane IgE+ cells (p = 0.04) by 17%. The strength of
membrane IgE expression in each cell group was com-
pared by noting the mean fluorescence intensity (MFI)
of the detecting anti-IgE antibody. No differences among
the three cell groups were observed (Figure 1B). As a
control, Figure 1B suggested that the decrease in num-
ber (Figure 1A) of membrane IgE+ cells was not likely
due to competition between omalizumab and PE-Figure 1 Omalizumab reduced the number of membrane IgE+
B cells. B cells were left non-treated (NT) or treated with IL-4 +
anti-CD40 in the presence or absence of 1 μg/mL omalizumab (Om).
After 4 days B cells were stained with PE-conjugated anti-human IgE.
(A) Number of mIgE+ cells. (B) Mean fluorescence intensity. Data are
expressed as the mean ± SEM (n = 6 tonsils). Statistically significant
difference (p value) was determined by t-test.conjugated anti-human IgE for membrane IgE binding
sites. The results of Figure 1 suggest that omalizumab
had a direct effect on the B cells and could reduce the
number of membrane IgE+ cells present in IL-4 plus
anti-CD40 treated B cell cultures.
Omalizumab reduced IL-6 secretion in human B cells
Treatment of human B cells with IL-4 plus anti-CD40
leads to IL-6 secretion within 48 h [14]. It recently was
reported that omalizumab reduced IL-6 and IL-8 secre-
tion in airway smooth muscle cells [15] and in human
skin mast cells [16]. We sought to determine if
omalizumab could interfere with the IL-6 production
induced by IL-4 plus anti-CD40 in B cells. Figure 2
shows that IL-6 production occurred in B cells after 3
and 7 days of stimulation with IL-4 plus anti-CD40. The
IL-6 level was unaffected at day 3 by omalizumab but by
day 7, the level had been reduced by ~15%. Omalizumab
reduced the amount secreted from 42.65 pg/mL to 36.50
pg/mL (p = 0.04 at day 7). Thus, omalizumab can affect
the IL-6 secretion induced by IL-4 plus anti-CD40. The
reduced cell number (Figure 1) of 17% was similar to the
amount of IL-6 lost in Figure 2. One interpretation
would be that the decreased IL-6 was due to a loss of
IL-6-producing cells rather than a general down regula-
tion of IL-6.
Omalizumab decreased B cell numbers
Since we observed a reduction in the number of mem-
brane IgE+ cells in the presence of omalizumab and it
was suggested previously that omalizumab may interact
with IgE-bearing cells leading to lysis of these cells [10],
we sought to determine if omalizumab could affect the
viability of IL-4 plus anti-CD40 treated B cells. In ourFigure 2 Omallizumab reduced IL-6 secretion in human B cells.
B cells were left non-treated (NT), treated with IL-4 + anti-CD40 in
the presence or absence of 1 μg/mL omalizumab (Om) or
omalizumab alone. After 3 and 7 days, culture supernatant fluid was
collected and quantified for IL-6 by ELISA. Data are expressed as the
mean ± SEM (n = 6 tonsils). Statistically significant difference
(p value) was determined by t-test.
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blocking reagent (to block Fc receptor-mediated antibody
binding) before treatment with omalizumab since it was
possible that omalizumab might bind Fc gamma receptors
present on B cells. However, we did not observe any differ-
ence in the effect of omalizumab on B cells with or with-
out pretreatment with FcR block (data not shown). Four
concentrations (0.1, 0.5, 1.0 and 2.0 μg/mL) of om-
alizumab were initially tested. Viable cell numbers in
response to IL-4 plus anti-CD40 were not significantly
different among the concentrations of omalizumab used
(data not shown). Thus, we chose to test a single concen-
tration of omalizumab (1 μg/mL) since this concentration
also was shown to consistently decrease IgE-induced IL-6
and IL-8 secretion in airway smooth muscle cells [15].
After 3 days of culture, cells were enumerated for viability
by trypan blue exclusion. Figure 3A shows that there was
a significant decrease in the number of viable B cells cul-
tured with IL-4 plus anti-CD40 in the presence of
omalizumab compared to cells cultured with IL-4 plus
anti-CD40 alone (p = 0.001). When B cells were cultured
with IL-4 plus anti-CD40 in the presence of a control anti-
body (human IgG1κ) no decrease in viable cell number
was seen. Non-treated cells remained viable during the 3
days of culture, and in the presence of omalizumab alone
the viable cell number did not change (data not shown).
We also examined the effect of omalizumab on subsets of
B cells. Naïve and memory B cells were isolated based on
expression of IgD and CD27. Figure 3B shows that both
naïve and memory B cells were equally sensitive to
omalizumab. Significant decreases in viable cells (p =0.04
and p = 0.03, respectively) were observed in both subsets
in the presence of omalizumab.
To determine if omalizumab was interfering with cell
proliferation, cells were labeled with CFSE beforeFigure 3 Omalizumab reduced viable human B cell numbers. Total B c
(NT) or treated with IL-4 + anti-CD40 in the presence or absence of 1 μg/m
trypan blue exclusion 3 days later. Data are expressed as the mean ± SEM
differences (p values) were determined by t-test.stimulation and the number of proliferating cells
analyzed by flow cytometry (Figure 4A). No significant
difference in the number of proliferating cells was
observed when cells were stimulated for 3 days in the
presence of omalizumab (Figure 4B). However, when the
small minority of proliferating membrane IgE+ cells was
evaluated a significant decrease (p = 0.05) in this subset
of cells was observed in the presence of omalizumab
(Figure 4C). On average the number of mIgE+ cells was
reduced by 25%. These results suggest that the decrease
in viable cell number in cultures treated with IL-4 plus
anti-CD40 in the presence of omalizumab was most
likely due to a form of cell death. In addition, om-
alizumab appeared to be able to selectively reduce the
number of proliferating membrane IgE+ cells in re-
sponse to IL-4 plus anti-CD40 stimulation.
Omalizumab did not induce apoptosis in human B cells
We hypothesized that the decrease in cell number
observed in cells treated with IL-4 plus anti-CD40 in the
presence of omalizumab could be due to the induction
of apoptosis. To determine if omalizumab was inducing
apoptosis in these cultures, B cells were left non-treated
or treated with IL-4 plus anti-CD40 in the presence or
absence of omalizumab or control antibody. After 3 days
of culture the cells were stained with 7-AAD and PE-
conjugated Annexin V and analyzed by flow cytometry.
Annexin V is an indicator of apoptotic cells and 7-AAD
is excluded by viable cells. Flow cytometric analysis
showed that omalizumab did not induce additional
Annexin V positivity in human B cells (Figure 5). In a
representative experiment, the percentage of Annexin V
positive cells was similar in cells treated with IL-4 plus
anti-CD40 alone (8.2%) (Figure 5A) and in the presence
of omalizumab (7.4%) (Figure 5B) or control antibodyells (A) and naïve and memory B cell subsets (B) were left non-treated
L omalizumab (Om) or human IgG. Live cells were enumerated by
(n = 7 tonsils, panel A; n = 4 tonsils, panel B). Statistically significant
Figure 4 Omalizumab reduced proliferating mIgE+ B cells. B cells were labeled with 2.5 μM CFSE prior to treatment with IL-4 + anti-CD40 in
the presence or absence of 1 μg/mL omalizumab (Om). After 3 days the cells were stained with APC conjugated anti-human IgE and analyzed by
flow cytometry (A) for the number of proliferating cells (B) and the number of proliferating mIgE+ cells (C). Panel A: Representative experiment
of 4 independent experiments. NT: non-treated cells. Panels B and C: Data are expressed as the mean ± SEM from 4 separate independent
experiments (4 tonsils). Statistically significant difference (p value) was determined by t-test.
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periments were analyzed together, the percentage of
Annexin V positive cells was similar in all three treat-
ment groups (Figure 5D). These results suggest that the
decrease in cell number in B cell cultures treated with
IL-4 plus anti-CD40 in the presence of omalizumab was
not due to induction of apoptosis.
Omalizumab reduced IL-4Rα and germline Cε mRNA
levels in human B cells
Since omalizumab appeared to reduce the number of
membrane IgE+ cells present in cultures treated with IL-
4 plus anti-CD40, we sought to determine if omalizumab
could affect the potential of B cells to commit to IgE
synthesis. To do this we examined the mRNA levels of
IL-4Rα and germline Cε since IL-4 is required for switch
recombination and germline Cε precedes final recom-
bination switching to the mature Cε transcript. B cells
were left non-treated or treated with IL-4 plus anti-
CD40 in the presence or absence of omalizumab. Cyto-
plasmic RNA was isolated from these cells 72 h later
and cDNA prepared. Quantitative RT-PCR was used to
evaluate mRNA levels using specific primers for IL-4Rα
chain and germline Cε. The IL-4Rα chain is a sharedsubunit of both type I and type II IL-4 receptors
expressed on B cells [17,18]. The data identified two
groups of samples according to responsiveness to
omalizumab. Figure 6A shows that omalizumab signifi-
cantly reduced both IL-4Rα chain and germline Cε
mRNA levels in 50% of cultures treated with IL-4 plus
anti-CD40. In Group 1 (n = 5) omalizumab significantly
reduced germline Cε (p = 0.03) and IL-4Rα (p = 0.005)
mRNA levels by 36% and 39%, respectively. In Group 2
(n = 5) there was a slight enhancement (though not sta-
tistically significant) of germline Cε mRNA and no
change in IL-4Rα mRNA levels in the presence of
omalizumab.
The low affinity receptor for IgE (FcεR2, CD23) is
known to play an important role in IgE regulation [19].
CD23 exists in soluble and membrane forms. The sol-
uble form of CD23 appears to positively regulate IgE
synthesis by B cells whereas the membrane form partici-
pates in a negative-feedback mechanism [20]. Human B
cells express both isoforms of CD23 (CD23a and
CD23b). We as well as others have shown that IL-4 can
up-regulate the expression of CD23 on human B cells
[21,22]. Since we observed changes in IL-4R expression
in the presence of omalizumab we examined the effect
Figure 5 Omalizumab did not induce apoptosis in human B cells. B cells were left non-treated (NT) or treated with IL-4 + anti-CD40 in the
presence or absence of 1 μg/mL omalizumab (Om) or human IgG. After 3 days B cells were stained with 7-AAD and PE-conjugated Annexin V
and analyzed by flow cytometry. Panels A – C: Representative experiment of 4 independent experiments. Percentage of Annexin V positive cells
is indicated in the lower right quadrant. (A) IL-4 + anti-CD40 (B) IL-4 + anti-CD40 + Om (C) IL-4 + anti-CD40 + IgG. Panel D: Mean percentage of
Annexin V+ cells ± SEM from 4 separate independent experiments (4 tonsils).
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alizumab did not affect the up-regulation of either
isoform of CD23 on human B cells mediated by IL-4
(Figure 6B). No statistically significant difference in
either CD23a or CD23b mRNA levels was observed in
either group treated with IL-4 plus anti-CD40 in the
presence of omalizumab. Taken together these results
suggest that omalizumab reduced the levels of IL-4Rα
chain and germline Cε mRNA in cultures treated with
IL-4 plus anti-CD40 but reduction was seen in only 50%
of the tonsillar samples tested. In contrast, levels of
CD23 mRNA were unaffected by the presence of
omalizumab in both groups of tonsillar samples.
Conclusions
Omalizumab is a recombinant DNA-derived humanized
anti-IgE antibody and has been used successfully to treat
patients with moderate-to-severe, and severe persistent
allergic asthma [3,4,23]. Also, patients with allergic rhin-
itis showed marked improvement of symptoms when
treated with omalizumab [24].
Omalizumab binds circulating IgE, and membrane IgE
on B cells, and prevents subsequent IgE-driven responses
such as the release of inflammatory mediators histamine
and leukotrienes by basophils and mast cells. However,
omalizumab does not bind IgE when IgE is bound to
either FcεRI or CD23 [2]. In addition, omalizumab appears
to display several other anti-inflammatory properties[2,6,8]. In allergic asthmatics treated with omalizumab a
significant decrease in cellular sensitivity to allergen chal-
lenge was observed [25] as well as decreases in circulating
serum levels of IL-5, IL-8 and IL-13 [26]. Peripheral blood
and sputum eosinophil counts [8,26] were decreased in
omalizumab- treated asthmatics and it was proposed that
the reduction in eosinophil counts was due to the induc-
tion of apoptosis in these cells [7]. Also, omalizumab
significantly reduced RNA and protein levels of IL-6, IL-8,
TNFα and IL-4 in a dose-dependent manner in IgE-
stimulated human airway smooth muscle cells isolated
from biospsy specimens of patients with asthma, chronic
obstructive pulmonary disease and healthy controls [15].
Finally, a significant reduction in the number of B
cells [6] and the number of mIgE+ B cells [8] has
been observed in patients with allergic asthma after
treatment with omalizumab.
It was proposed that omalizumab bound to mIgE on B
cells might mimic the pathway that leads to apoptosis or
anergy in B cells treated with anti-IgM or anti-IgG [27,28].
In the present work, we have shown that omalizumab
appeared to reduce the number of B cells that synthesize
IgE. One measure of IgE-producing B cells is expression
of IgE containing the membrane associated exons and
displayed as an integral membrane surface protein to cre-
ate membrane IgE+ (mIgE+) B cells. We observed 17%
fewer mIgE+ B cells in cultures treated with IL-4 plus
anti-CD40 in the presence of omalizumab compared to
Figure 6 Omalizumab reduced germline Cε and IL-4Rα mRNA
levels in ~ 50% of tonsillar samples. B cells were treated with IL-4
+ anti-CD40 in the presence or absence of 1 μg/mL omalizumab
(Om). After 3 days RNA was isolated and quantified by qRT-PCR for
(A) germline Cε and IL-4Rα mRNA. (B) CD23a and CD23b mRNA.
Data are expressed as the mean ± SEM (n = 5 tonsils for group 1
and n = 5 tonsils for group 2). Statistically significant differences
(p values) were determined by t-test.
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the presence of omalizumab there were fewer proliferating
mIgE+ cells. This is similar to the work of others [8] using
histochemical analysis of bronchial biopsies from patients
with mild to moderate persistent asthma that were treated
with omalizumab. A significant reduction in IgE+ cells
was noted in samples from these patients compared to the
placebo group; however, in that study the IgE+ cells were
not further characterized. In our study, five possibilities
exist to explain the observed omalizumab-induced de-
crease in the number of membrane IgE+ B cells: 1)
reduced proliferation in response to IL-4 plus anti-CD40;
2) induction of anergy; 3) induction of apoptosis, 4) pre-
vention of existing B cells to class switch to expression of
IgE; or 5) omalizumab-induced shedding or internalization
of membrane IgE.
We demonstrated that omalizumab reduced cell num-
bers in B cell cultures treated for 3 days with IL-4 plus
anti-CD40. This was shown by enumerating viable cell
number by exclusion of the viable dye trypan blue. The
loss of cell numbers did not appear to be due to the
induction of apoptosis since the percentage of AnnexinV positive cells was similar in non-treated cells and cells
treated with IL-4 plus anti-CD40 in the presence or
absence of omalizumab or control antibody. Thus, in
our B cell cultures omalizumab did not appear to induce
apoptosis. Rather the reduction in viable cell number
may have been the result of the cells entering an anergic
state. Anergic B cells have a limited life span of only 3 –
4 days [29].
When mRNA levels of genes involved in IgE synthesis
were examined we observed a significant reduction by
cultures containing omalizumab of IL-4Rα and germline
Cε mRNA levels suggesting a downregulation in IL-4
responsiveness. The reduced levels of IL-4Rα and Cε
mRNA appeared to be selectively targeted by om-
alizumab since mRNA levels of both isoforms of the low
affinity IgE receptor CD23 were unaffected. Roth and
Tamm [15] also noted that omalizumab did not affect
expression of either high or low affinity IgE receptors by
human airway smooth muscle cells cultured in vitro with
omalizumab. Since we also observed that omalizumab
reduced the numbers of mIgE+ B cells in cultures stimu-
lated by IL-4 plus anti-CD40, it is likely that the reduc-
tion of IL-4Rα and Cε mRNA levels is a direct reflection
of the reduced numbers of mIgE+ cells in cultures
containing omalizumab.
It was of interest that omalizumab reduced IL-4Rα
and germline Cε mRNA levels in only 50% of the 10
tonsils analyzed for the gene expression studies. These
results suggest that not all individuals may be respon-
sive to omalizumab. Unfortunately, all identifiers were
removed from the tonsil tissue before processing so we
were unable to determine the allergic status of the
individuals from which B cells were responsive to
omalizumab. However, our results are in agreement
with response rates to omalizumab from clinical trial
data. The data indicated that not all patients with per-
sistent asthma who were treated with omalizumab
showed improvement [30,31]. The patients were
grouped as responders and non-responders and the re-
sponse rates to omalizumab ranged from 53.1% to
68.5%.Competing interests
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